secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2022-06-30T23:59:59+00:00
Accession:  0001213900-22-036020
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics CEO Steve Carchedi and CFO Jens Knudsen resign; James Cullem interim CEO, Joan Brown interim CFO
--------------------------------------------------------------------------------

- CEO Steve Carchedi resigned effective June 29, 2022; CFO Jens Knudsen resigned effective June 27, 2022, both to pursue other opportunities.
- Board appointed James Cullem, current Chief Business Officer, as interim CEO; he continues as CBO.
- Board appointed Joan Brown, current Director of Financial Reporting, as interim CFO; she continues as Director of Financial Reporting.
- Permanent CEO and CFO expected to be named in H1 2023, per press release.
- Co-founders Dr. Steen Knudsen (CSO) and Dr. Marie Foegh (CMO) remain in roles; Thomas Jensen becomes SVP of Investor Relations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/ea162285-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-036020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer